In 2023, Canada led the global alimentary tract and metabolism medicine sales at 5.85 billion USD, reflecting a substantial 12.08% year-on-year increase. Japan followed with 4.94 billion USD, recording a 7.75% growth. The United Kingdom saw marginal growth to 2.72 billion USD. Other European countries showed modest sales figures with moderate positive trends, like Belgium with 2.71% and Austria at 6.48%. The 2023 variations suggest stable demand, particularly in larger and developed markets, with Canada and Japan showing strong momentum.
Future trends include:
- The aging population worldwide, enhancing demand in established markets.
- Emerging markets, especially in Asia and Latin America, are anticipated to gain traction due to healthcare advancements.
- Innovation in drug development and personalized medicine likely to drive market dynamics.
Top countries in Alimentary Tract and Metabolism Medicine Sales by Country
| # | 9 Countries | Million US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Canada | 5,850 | 2023 | +9.88% | +12.08% | View data |
| 2 | 2 Japan | 4,940 | 2023 | +0.079% | +7.75% | View data |
| 3 | 3 United Kingdom | 2,720 | 2023 | +0.99% | +0.55% | View data |
| 4 | 4 Belgium | 926 | 2023 | +2.24% | +2.71% | View data |
| 5 | 5 Austria | 511.2 | 2023 | +5.36% | +6.48% | View data |
| 6 | 6 Ireland | 355.1 | 2023 | +2.78% | +5.79% | View data |
| 7 | 7 Slovakia | 295.8 | 2023 | +2.99% | +4.93% | View data |
| 8 | 8 Slovenia | 96.2 | 2023 | +4.45% | +5.59% | View data |
| 9 | 9 Estonia | 54.5 | 2023 | +3.42% | +3.91% | View data |
